olmesartan has been researched along with daunorubicin in 3 studies
| Studies (olmesartan) | Trials (olmesartan) | Recent Studies (post-2010) (olmesartan) | Studies (daunorubicin) | Trials (daunorubicin) | Recent Studies (post-2010) (daunorubicin) |
|---|---|---|---|---|---|
| 841 | 185 | 554 | 8,239 | 886 | 1,310 |
| Protein | Taxonomy | olmesartan (IC50) | daunorubicin (IC50) |
|---|---|---|---|
| 72 kDa type IV collagenase | Homo sapiens (human) | 1.9 | |
| Multidrug resistance-associated protein 1 | Homo sapiens (human) | 8 | |
| Histone deacetylase 1 | Homo sapiens (human) | 0.047 | |
| Histone deacetylase 8 | Homo sapiens (human) | 0.22 | |
| Histone deacetylase 6 | Homo sapiens (human) | 0.02 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Aizawa, Y; Arozal, W; Harima, M; Kodama, M; Sukumaran, V; Suzuki, K; Tachikawa, H; Thandavarayan, RA; Veeraveedu, PT; Watanabe, K | 1 |
| Arozal, W; Arumugam, S; Gounder, VK; Harima, M; Nomoto, M; Pitchaimani, V; Suzuki, K; Thandavarayan, RA; Watanabe, K | 1 |
3 other study(ies) available for olmesartan and daunorubicin
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Beneficial effects of angiotensin II receptor blocker, olmesartan, in limiting the cardiotoxic effect of daunorubicin in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antibiotics, Antineoplastic; Blotting, Western; Daunorubicin; Heart; Imidazoles; Immunohistochemistry; Male; Myocardium; Oxidative Stress; Rats; Rats, Sprague-Dawley; Tetrazoles | 2010 |
Olmesartan protects against oxidative stress possibly through the Nrf2 signaling pathway and inhibits inflammation in daunorubicin-induced nephrotoxicity in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Blood Urea Nitrogen; Cholesterol; Creatinine; Daunorubicin; Glutathione Peroxidase; Imidazoles; Kidney; Kidney Diseases; Male; Matrix Metalloproteinase 2; NF-E2-Related Factor 2; Oxidative Stress; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Signal Transduction; Tetrazoles; Triglycerides | 2014 |